Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Comparison of diagnostic performance of five molecular assays for detection of SARS-CoV-2

Neena Kanwar, Dithi Banerjee, Anjana Sasidharan, Ayah Abdulhamid, Marissa Larson, Brian Lee, Rangaraj Selvarangan, Rachael M. Liesman

Abstract
We compared the performance of the Abbott Real Time SARS-CoV-2 assay (Abbott assay), Aptima SARS-CoV-2 assay (Aptima assay), BGI Real-Time SARS-CoV-2 assay (BGI assay), Lyra SARS-CoV-2 assay (Lyra assay), and DiaSorin Simplexa COVID assay for SARS-CoV-2 detection. Residual nasopharyngeal samples (n = 201) submitted for routine SARS-CoV-2 testing by Simplexa assay during June–July 2020 and January 2021 were salvaged. Aliquots were tested on other assays and compared against the CDC 2019-nCoV Real-Time RT-PCR assay. Viral load in positive samples was determined by droplet digital PCR. Among 201 samples, 99 were positive and 102 were negative by the CDC assay. The Aptima and Abbott assays exhibited the highest positive percent agreement (PPA) at 98.9% while the BGI assay demonstrated the lowest PPA of 89.9% with 10 missed detections. Negative percent agreement for all 5 platforms was comparable, ranging from 96.1% to 100%. The performance of all five assays was comparable.

Keywords:
SARS-CoV-2 detection, Molecular assay comparison, COVID-19

1. Introduction
Global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a coronavirus disease 2019 (COVID-19) pandemic (Coronavirus disease COVID-19 outbreak, 2020). Molecular methods are currently considered the reference method for SARS-CoV-2 detection (Araj et al., 2020; Hanson et al., 2020; Patel et al., 2020). Many commercial SARS-CoV-2 molecular assays received Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) to meet the diagnostic needs related to this pandemic (Emergency Use Authorization: Emergency Use Authorization EUA information, and list of all current EUAs, 2020). Consequently, clinical laboratories across the United States faced challenges in identifying reliable diagnostic assays for SARS-CoV-2 detection given the limited availability of published performance and comparison data. Additional challenges include supply chain difficulties, which many laboratories have addressed by implementing multiple assays (SARS-CoV-2 molecular testing: summary of recent SARS-CoV-2 molecular testing survey, 2020; Lieberman et al., 2020). Comparative evaluations of analytical performance as well as real world clinical performance of EUA assays are essential to help guide assay selection as laboratories expand testing capacity (Babiker et al., 2020).

Clinical study data comparing several of the molecular assays have recently been published (Basu et al., 2020; Chen et al., 2020; Craney et al., 2020; Creager et al., 2020; Moran et al., 2020; Poljak et al., 2020; Rhoads et al., 2020; Smith et al., 2020; Yip et al., 2020; Zhen et al., 2020). To our knowledge, this is the first study comparing the performance of Lyra SARS-CoV-2 Assay (Lyra assay), and the second large scale clinical study with the BGI Real-Time SARS-CoV-2 assay (BGI assay). Our current study is one of a few that evaluated the clinical diagnostic performance of five or more assays (Garg et al., 2021; Lieberman et al., 2020; Onwuamah et al., 2021). The study objective was to analyze and compare the diagnostic performance of five EUA approved molecular assays, the Abbott Real-time SARS-CoV-2 assay (Abbott assay), Aptima SARS-CoV-2 Assay (Aptima assay), BGI assay, Lyra assay, and DiaSorin Simplexa COVID-19 Direct assay (Simplexa assay), using CDC 2019-nCoV Real-Time RT-PCR assay (CDC assay) as the reference standard on clinical salvage respiratory samples.

2. Methods
2.1. Study design
This prospective salvage sample study included 201 nasopharyngeal samples submitted to the University of Kansas Health System
Table 1
Molecular in vitro diagnostic ELISA assay characteristics.

| Manufacturer | Sample type\(a\) | Sample volume (µL) | Separation extraction | Sample collection and storage | Sample reason for testing | Sample gender, female (%) | Sample age (in years), (range) |
|--------------|-------------------|-------------------|------------------------|-----------------------------|--------------------------|--------------------------|-----------------------------|
| CDC          | NP, OP, NP wash/aspirate, nasal aspirate, sputum, BAL | Yes | Yes | 100 | Admit 7500 Fast Dx | Symptomatic 77/99 (77.8) | 53 (18−90) |
| Abbott       | NS, NP, OP, BAL   | No | 1000 | 1000 | Abbott M5000 | Symptomatic 51/102 (50.0) | 56 (15−92) |
| Hologic      | NP, NS, MTS, OP, NP wash/aspirate, nasal aspirate | No | Yes | 500 | Panther, Panther Fusion | Symptomatic 128/201 (63.7) | 99 (15−92) |
| BGI          | NS, NP, MTS, OP, nasal aspirate | No | Yes | 180 | AIB 7500 Fast, AIB 7500, ABI Q55, Roche LightCycler 480 | Symptomatic 101/102 (100.0) | 92 (15−92) |
| Quidel       | NS, NP, OP       | No | Yes | 180 | AIB 7500 Fast Dx, ABI 7500 standard, Roche LightCycler 480, Qagen Rotor-Gene Q, BioRad iCycler Touch | Symptomatic 98/201 (48.8) | 92 (15−92) |
| Diasorin     | NS, nasal wash/aspirate, BAL | No | Yes | 50 | LIAISON MiDx | Symptomatic 98/201 (48.8) | 87 (15−92) |

\(a\) NS = nasal swab; NP = nasopharyngeal swab; OP = oropharyngeal swab; BAL = bronchoalveolar lavage fluid; MTS = midturbinate swab.

In Table 1, the characteristics of all the assays evaluated are compared to CDC reference standard as reported previously (Broughton et al., 2020; Degli-Angeli et al., 2020; Lieberman et al., 2020; Mitchell and George, 2020; Pujadas et al., 2020; Rhoads et al., 2020). The Bio-Rad SARS-CoV-2 ddPCR test was performed on all samples that tested positive by any assay. Ct values obtained from each assay were compared with the quantitative results from ddPCR assay.

2.3. Study population

Symptomatic as well as nonsymptomatic patients of both genders were included in the study. Samples were submitted from both inpatient and emergency departments at the TUKHS. Testing location and reason for testing (asymptomatic screen, symptomatic testing) were recorded (Table 2).

2.4. Aptima® SARS-CoV-2 assay (Panther® System)

This assay is a sample-to-answer molecular assay performed on the Panther instrument (Hologic Inc.; Marlborough, MA) that utilizes the combined technologies of target capture, transcription mediated amplification (TMA), and dual kinetic assay (DKA) to amplify two unique regions of the ORF1ab gene of the SARS-CoV-2 viral genome. Briefly, 500 µL of thawed aliquot was transferred to the specimen lysis tube and loaded on the Panther instrument. Based on the total Relative Light Units (RLU) and the kinetic curve type, the assay requires any of the two regions of the ORF1ab gene to be detected for reporting a positive sample.

(TUKHS) clinical laboratory for routine SAR-CoV-2 testing on the Simplex COVID-19 Direct assay (DiaSorin Molecular LLC; Cypress, CA) during the months of June/July 2020 and January 2021. Of the 201 specimens analyzed, 100 were positive and 101 were negative on initial testing by Simplexa. Six aliquots of fresh sample were made within 72 hours of the sample collection. Three aliquots were shipped to the Children's Mercy Hospital clinical laboratory on dry ice for testing on three platforms (Aptima assay, CDC assay, and Lyra assay). All aliquots were thawed only once before testing on respective platforms. Testing on Abbott assay and BGI assay were performed at the TUKHS clinical laboratory. Characteristics of all the assays evaluated in the study have been described in Table 1. Testing results from each of the assays were compared with the CDC reference standard as reported previously (Broughton et al., 2020; Degli-Angeli et al., 2020; Lieberman et al., 2020; Mitchell and George, 2020; Pujadas et al., 2020; Rhoads et al., 2020).

The study was approved by the Institutional Review Board of both institutions. 2.2. Specimen collection and storage

Nasopharyngeal swabs (Shenzhen Medico Technology Co.; Shenzhen City, China) were transported in 3 mL of viral transport media (Jinan Babio Biotechnology Co., Ltd.; Shandong, China), stored at 2 to 8°C, and tested with the Simplexa assay. Clinical testing and aliquoting for testing with comparator assays were performed within 72 hours of sample collection. Aliquots were stored at −70°C until further testing.

2.3. Study population

Symptomatic as well as nonsymptomatic patients of both genders were included in the study. Samples were submitted from both inpatient and emergency departments at the TUKHS. Testing location and reason for testing (asymptomatic screen, symptomatic testing) were recorded (Table 2).

2.4. Aptima® SARS-CoV-2 assay (Panther® System)

This assay is a sample-to-answer molecular assay performed on the Panther instrument (Hologic Inc.; Marlborough, MA) that utilizes the combined technologies of target capture, transcription mediated amplification (TMA), and dual kinetic assay (DKA) to amplify two unique regions of the ORF1ab gene of the SARS-CoV-2 viral genome. Briefly, 500 µL of thawed aliquot was transferred to the specimen lysis tube and loaded on the Panther instrument. Based on the total Relative Light Units (RLU) and the kinetic curve type, the assay requires any of the two regions of the ORF1ab gene to be detected for reporting a positive sample.

2.2. Specimen collection and storage

Nasopharyngeal swabs (Shenzhen Medico Technology Co.; Shenzhen City, China) were transported in 3 mL of viral transport media (Jinan Babio Biotechnology Co., Ltd.; Shandong, China), stored at 2 to 8°C, and tested with the Simplexa assay. Clinical testing and aliquoting for testing with comparator assays were performed within 72 hours of sample collection. Aliquots were stored at −70°C until further testing.

**Table 2.**
Study patient demographics.

|                          | SARS-CoV-2 positive | SARS-CoV-2 negative | All subjects |
|--------------------------|---------------------|---------------------|-------------|
| N                        | 99                  | 102                 | 201         |
| Age (in years), (range)  | 53 (18−90)         | 56 (15−92)         | 57 (15−92)  |
| Gender, female (%)       | 47/99 (47.5)       | 51/102 (50.0)      | 98/201 (48.8)|
| Reason for testing       | Symptomatic        | Admission screen   | Emergency department |
|                          | 77/99 (77.8)       | 51/102 (50.0)      | 28/102 (27.5)|
|                          | 22/99 (22.2)       | 51/102 (50.0)      | 74/102 (72.5)|
|                          | 13/99 (13.1)       | 73/102 (36.3)      | 160/201 (79.6)|
|                          | 86/99 (86.9)       | 41/102 (20.4)      | 160/201 (79.6) |
2.5. Lyra® SARS-CoV-2 assay

This Real-Time RT-PCR assay is targeted toward SARS-CoV-2 non-structural polyprotein gene (\(pp1ab\)). Briefly, 180 \(\mu\)L of sample and 20 \(\mu\)L of process control (PRC) were extracted by NucliSENS easyMAG (bioMerieux, Inc; Marcy-l’Étoile, France) and eluted in 50 \(\mu\)L of extract and 15 \(\mu\)L of rehydrated lyophilized master mix containing oligonucleotide primers and fluorophore and quencher-labeled probes was amplified by the Applied Biosystems® 7500 Fast Real-Time PCR System (ABI 7500; ThermoFisher Scientific; Waltham, MA) with specified assay protocol (Table 1). This assay requires detection of the \(pp1ab\) gene to report a positive sample.

2.6. CDC 2019-nCoV Real-Time RT-PCR assay

This RT-PCR assay targets SARS-CoV-2 virus nucleocapsid N1 and N2 genes and the human RNase P gene. Three separate master mix sets for N1, N2, and RNase P were prepared as per protocol IFU. The PCR reaction was performed using 15 \(\mu\)L of each master mix and 5 \(\mu\)L of extracted sample. Amplification was performed on the Applied Biosystems QuantStudio 5 Real-Time PCR System (QNS-5; ThermoFisher Scientific). This assay requires both the N1 and N2 regions of the nucleocapsid gene to be detected to be considered a positive sample.

2.7. Abbott Real-Time SARS-CoV-2 assay

This assay is designed to amplify regions of the RdRp and N genes of SARS-CoV-2. Specimens were heat inactivated at 65°C for 30 minutes prior to testing. At least 1 mL of heat inactivated sample was loaded onto the m2000sp extraction instrument and amplification and detection were performed on the m2000rt instrument (Abbott Molecular Inc; Green Oaks, IL). The two SARS-CoV-2 specific probes are labeled with the same fluorophore, so detection of either or both genes is considered a positive result.

2.8. BGI Real-Time SARS-CoV-2 assay

This assay is designed to amplify a single ORF1ab region of the SARS-CoV-2 genome. Specimens were extracted on an MGISP-960RS extraction platform using the MGEasy Nucleic Acid Extraction Kit with 180 \(\mu\)L of specimen eluted in 30 \(\mu\)L. Amplification and detection was performed on the Applied Biosystems 7500 Real-Time PCR System, using 10 \(\mu\)L of extracted sample RNA with 20 \(\mu\)L of BGI PCR mix, per manufacturer’s IFU. Data analysis was performed using the Applied Biosystems 7500 Software (v2.3). Three separate master mix sets for target and internal control (\(\beta\)-actin), data were analyzed based on Ct value. Samples were considered positive if internal control Ct < 35 and the target Ct value is < 37.3. Specimens were considered “equivocal” if the SARS-CoV-2 target was detectable at Ct ≥ 37. For this study, these specimens were re-extracted and retested using the BGI assay as per manufacturer instructions. For the purposes of clinical care, such specimens are retested on an alternative platform.

2.9. Diasorin Simplexa COVID-19 direct assay

This assay is designed to detect the ORF1ab and S regions of the SARS-CoV-2 genome. Briefly, 50 \(\mu\)L of sample was transferred into the direct amplification disk (DAD) in addition to 50 \(\mu\)L of reaction mix. The sealed DAD was loaded into the LIAISON® MDX instrument (DiaSorin Molecular LLC) and run using the COVID-19 protocol. This assay requires detection of only one of the gene targets to be considered positive.

2.10. Bio-Rad droplet digital PCR

The Bio-Rad SARS-CoV-2 ddPCR test is reverse transcription droplet digital assay for the detection of two regions of the viral nucleocapsid gene (N1 and N2). Amplification was performed using 5.5 \(\mu\)L of the easyMAG extract and 16.5 \(\mu\)L Bio-Rad One-Step RT-ddPCR supermix and loaded on QX200 TM AutoDG Droplet Generator (Bio-Rad) and fractionated into up to 20,000 nanoliter-sized droplets which were collected on a new 96-well plate and heat sealed. One-step reverse transcription and amplification were performed on a C1000 Touch™ Thermal Cycler (Bio-Rad) with 96-deep well reaction module using the following thermal cycling conditions: 50°C for 60 minutes (reverse transcription); 95°C for 10 minutes; and 40 cycles of 94°C for 30 seconds, and 55°C for 60 seconds followed by 98°C for 10 minutes (enzyme deactivation) and 4°C for 30 minutes (droplet stabilization). The plate was then transferred to the QX200™ Droplet Reader (Bio-Rad Laboratories; Hercules, CA) to measure the fluorescence intensity of each droplet in two channels (FAM and HEX). Fluorescence data were analyzed using the QuantaSoft droplet reader software (V1.7.4, Bio-Rad Laboratories, Inc.) where reactions containing more than 10,000 droplets were considered suitable for data analysis. High concentrations of viral RNA may cause samples to be reported without any negative droplets. Such samples were diluted (1:100 and 1:1000) and processed a second time for droplet generation and PCR, per manufacturer’s protocol.

2.11. Data analysis

The true-positive (TP), true-negative (TN), false-positive (FP), and false-negative (FN) categories were determined based on the CDC reference standard used in the study. Two-by-two data tables were used to determine the positive percent agreement (PPA) and the negative percent agreement (NPA) among all five SARS-CoV-2 diagnostic assays. PPA and NPA estimates along with 95% confidence intervals for the Kappa score were calculated for each of the diagnosis assays when compared to the CDC assay outcome. Percentile-based confidence intervals for the Kappa score were calculated using bootstrap estimations (1000 replications). All Kappa score calculations were completed using Stata software (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC).

3. Results

A total of 201 samples were tested. Results from each molecular platform were compared to the CDC reference standard result. Both symptomatic (\(n = 128\)) and asymptomatic (\(n = 73\)) subjects were included in the study. There was approximately equal distribution of male and female study subjects (Female: \(n = 98/201, 48.8\%\)). The median age of the patients included in the study was 57 years (Table 2).

The CDC assay reported 99 samples as positive and 102 as negative for SARS-CoV-2. As compared to CDC assay, Aptima and Abbott assays exhibited the highest PPA at 98.9%; PPA for Lyra and Simplexa assays were 97.9% and 91.9%, respectively. The BGI assay demonstrated the lowest PPA of 89.9% with 10 missed detections. The NPA for all 6 platforms were comparable ranging from 96.1% to 100%. (Table 3). The Aptima assay was determined to have the highest number of false positive (FP) results compared to the CDC reference standard (\(n = 4\)). Cohen’s kappa values indicated almost perfect agreement (≥0.90) with the reference standard for all five molecular assays.

A total of 106 samples positive by at least one platform were tested by ddPCR to determine viral load. Of the 106 samples, 21 samples were reported as negative on at least one platform and were
included for overall discrepant analysis (Table 4). By testing with the CDC assay, 14 of the 21 discordant samples were negative and 7 were positive. The ddPCR result was in agreement with the original CDC result in 18/21 (85.7%) overall discordant samples. The remaining 3 samples were negative by ddPCR (viral load below the 100 copies/ml threshold) and positive by CDC testing. Each of these samples was detected at a high Ct value (or low RLU value) by the CDC assay and most other tested assays and the low viral burden of these samples may account for the negative ddPCR result (Table 4).

Overall viral load in all positive samples ranged between 150 copies/ml to 98.5 million copies/mL for N1 gene and 162 copies/mL to 93.8 million copies/mL for N2 gene. Positive samples with the same viral load demonstrated variable Ct values across the different platforms tested. An overall correlation of the Ct values from different platforms may account for the negative ddPCR result (Table 4).

The BGI assay demonstrated the highest number of false negative results (n = 10). Three samples had a Ct value between 37 and 40 on initial testing, interpreted as “equivocal”. Repeat testing of these samples on BGI platform yielded negative results. On the BGI assay, five samples required repeat testing after initial results were reported with Ct values ranging between 37.17 and 39.72. These samples were re-extracted and retested using the BGI protocol. All five samples yielded negative results on retesting. For the CDC assay, two samples were negative on N1 target but positive on N2 target. Repeat testing with old and new extract generated positive results on both targets (N1 Ct: 38.12 and N2 Ct: 37.4) for one sample while the second sample was negative for both targets.

The Aptima platform reported 4 FP results, all of which were detected from the runs using uncapped tubes (catalogue no. PRD 06554 and 06660), possibly resulting in carryover contamination. A 0.67% carryover rate has been reported in the manufacturer’s IFU. Forty-two percent of samples (84/201) were run in the Aptima capped tube workflow which was switched to the uncapped workflow during the study when capped tubes became unavailable. The RLU values for three of the four positive specimens were 671, 786, and 987, considered to be low positives (cut-off RLU for Aptima assay is 560) (Pham et al., 2020); RLU for the fourth specimen was 1212.

4. Discussion

Multiple commercial SARS-CoV-2 molecular assays are currently marketed under FDA EUA without undergoing the typical rigorous clinical trials for obtaining FDA clearance/approval. Comparative

### Table 3
Performance characteristics of assays.

| Assay | NAAT result | CDC result | PPA (%) (95% CI) | NPA (%) (95% CI) | Kappa (95% CI)* |
|-------|-------------|------------|------------------|------------------|-----------------|
|       | Positive    | Negative   |                  |                  |                 |
| Lyra  | Positive    | 91         | 0                | 91.9 (84.2–96.2) | 0.92 (0.86, 0.97) |
|       | Negative    | 8          | 102              |                  |                 |
| Aptima| Positive    | 98         | 4                | 98.9 (93.7–99.9) | 0.95 (0.90, 0.99) |
|       | Negative    | 1          | 98               |                  |                 |
| Abbott| Positive    | 98         | 3                | 98.9 (93.7–99.9) | 0.96 (0.92, 0.99) |
|       | Negative    | 1          | 99               |                  |                 |
| Simplex| Positive  | 97         | 3                | 97.9 (92.2–99.6) | 0.95 (0.90, 0.99) |
|       | Negative    | 2          | 99               |                  |                 |
| BGI   | Positive    | 89         | 0                | 89.9 (81.8–94.8) | 0.90 (0.83, 0.96) |
|       | Negative    | 10         | 102              |                  |                 |

* Percentile-based confidence intervals from bootstrap estimations.

### Table 4
Discrepant sample analysis by ddPCR.

| Sample | # Platforms positive | CDC (CT) | NAAT result | Positive | Negative |
|--------|----------------------|----------|-------------|----------|----------|
|        |                      | N1       | N2          |          |          |
| 1      | 5                    | Pos      | 36.2        | 36.1     | ND       |
| 2      | 5                    | Pos      | 30.6        | 30.2     | 22.9     |
| 3      | 5                    | Pos      | 37.2        | 36.5     | 12.6     |
| 4      | 5                    | Pos      | 34.9        | 37.9     | 27.4     |
| 5      | 5                    | Pos      | 35.9        | 34.6     | 28.9     |
| 6      | 5                    | Pos      | 34.1        | 34.7     | 27.8     |
| 7      | 5                    | Pos      | 35.1        | 36.1     | 27.2     |
| 8      | 5                    | Pos      | 35.6        | 34.4     | 27.2     |
| 9      | 5                    | Pos      | 12.6        | 10.5     | 9.5      |
| 10     | 4                    | Pos      | 35.2        | 35.8     | 27.1     |
| 11*    | 4                    | Pos      | 36.3        | 36.8     | 18.2     |
| 12*    | 4                    | Pos      | 36.9        | 39.9     | 28.7     |
| 13*    | 3                    | Pos      | 38.1        | 37.4     | 27.8     |
| 14     | 3                    | Neg      | ND          | ND       | ND       |
| 15     | 2                    | Pos      | 38.2        | 38.9     | ND       |
| 16     | 1                    | Neg      | ND          | ND       | ND       |
| 17     | 1                    | Neg      | ND          | ND       | ND       |
| 18     | 1                    | Neg      | ND          | ND       | ND       |
| 19     | 1                    | Neg      | ND          | ND       | 5.56     |
| 20     | 1                    | Neg      | ND          | ND       | ND       |
| 21     | 1                    | Neg      | ND          | ND       | ND       |

* ND = not detected; Pos = positive; Neg = negative.

* Samples with discordant results between CDC and ddPCR assays

ddPCR result cutoff: negative if both targets are <100 copies/ml and <2 positive droplets.
performance studies for SARS-CoV-2 detection are of importance to the clinical community as they provide real world performance data to help guide testing decisions. This study compared the performance of five SARS-CoV-2 NAATs for 201 NP swab specimens collected from both symptomatic and asymptomatic subjects. Other comparator studies recently evaluated four of the six assays included in our study assay and reported comparable performances (Bordi et al., 2020; Bulterys et al., 2020; Cradic et al., 2020; Creager et al., 2020; Degli-Angeli et al., 2020; Harrington et al., 2020; Lieberman et al., 2020; Moore et al., 2020; Mostafa et al., 2020; Pujadas et al., 2020; Rhoads et al., 2020; Uhteg et al., 2020; Zhen et al., 2020). To our knowledge, this is the first report of relative clinical performance data of the Lyra assay for SARS-CoV-2 detection and one of the few that compares five platforms simultaneously.

The ddPCR is thought to be more sensitive compared to many RT-PCR assays, as there is less dependence on efficiency of PCR amplification due to end point measurement of nucleic acid quantitation. Additionally, ddPCR is less affected by reaction inhibitors due to microdilution in each droplet (Taylor et al., 2017). The ddPCR assay results are reported by gene copy, an absolute quantification, rather than Ct value, which varies significantly among different NAAT platforms (Binnicker, 2020). Ct value varied among different NAATs evaluated in this study, which may be due to protocol differences (e.g., input volume), differences in extraction method (e.g., sample-to-answer vs full extraction), amplification technology (e.g., TMA vs RT-PCR), differences in target region of amplification, sampling error (especially for specimens with low viral load), and assay design variability (e.g., florescence data capture starts after several amplification cycles, as is the case for the Abbott and Lyra assays) (Table 2). The Ct variability across different platforms for samples with the same viral load as demonstrated in this study (Fig. 1A and B) supports the determination that Ct values should be interpreted with caution (Binnicker, 2020; Binnicker, 2020). If required, absolute quantification of viral copies by ddPCR may be a more reliable method of determining viral burden. However, ddPCR missed detection of three true positive samples with low viral loads and corresponding high Ct values on other platforms, demonstrating a limitation that viral loads below the limit of detection of the assay (<100 copies/mL) would go undetected by ddPCR.

Few limitations of our study require consideration. Samples were selected based on the Simplexa assay results and repeat testing after specimen freeze-thaw was not performed on the Simplexa platform, unlike comparable platforms. Theoretically, freeze-thaw may lead to nucleic acid degradation or, alternatively, may remove nonspecific inhibition, both of which may influence detection rate; nonetheless, all assays were comparable in detection rate. Additionally, this study included predominantly samples collected from adult population with only one sample from a patient <18 years old. Therefore, caution is advised while extrapolating study results to a pediatric population. The CDC PCR assay was used as a reference standard method in this study. The absence of true reference standard for SARS-CoV-2 detection is well recognized (Axell-House et al., 2020; Mitchell et al., 2020). Laboratorians have used different approaches for establishing an arbitrary reference standard for diagnostic assay comparison studies such as using composite/consensus reference standard or comparing results to one of the RT-PCR results (Axell-House et al., 2020). We considered the CDC assay as an arbitrary reference method, as it has demonstrated excellent performance characteristics in previous studies (Etievant et al., 2020; Lieberman et al., 2020; Moore et al., 2020; Uhteg et al., 2020). We recognize that a more sensitive assay could alter the study results. We also evaluated results using consensus reference standard, defined as positive result in ≥4 of 6 NAAT assays and consensus negative was a negative result in ≥4 of 6 NAAT assays (data not shown). Results from consensus reference method demonstrated comparable results to CDC reference method; additionally, the CDC assay and consensus reference method were found to have a PPA and NPA of 100% and 99%, respectively (data not shown). Study strengths include direct comparison of five commonly
used EUA approved NAAT platforms for SARS-CoV-2 detection. The sample pool came from both symptomatic and nonsymptomatic patients.

With the presence of multiple diagnostic assays in the field, the decision to select a SARS-CoV-2 molecular assay depends upon the laboratory setting and infrastructure, resources with respect to staff and cost involved, testing volume, patient population, and indication for testing. Assays detecting only a single gene target pose a theoretical risk for false negative results with the emergence of viral variants, although this was not evaluated in this study. Our study evaluated the performance of five platforms in a controlled study design and our data shows comparable results for SARS-CoV-2 detection across all the platforms tested.

Author contributions statement

Neena Kanwar: Data curation; Formal analysis; Investigation; Methodology; Project administration; Supervision; Validation; Roles/ Writing – original draft; Writing – review & editing.

Dithi Banerjee: Data curation; Formal analysis; Methodology; Writing– review & editing.

Anjana Sasakiadhurun: Data curation; Writing - review & editing.

Ayah Abdhammad: Data curation

Marissa Larson: Data curation

Brian Lee: Data curation; Software and Formal analysis

Rangaraj Selvarangan: Conceptualization; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Visualization; Writing - review & editing.

Rachael M Liesman: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Supervision; Validation; Writing - review & editing.

Funding declaration

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

The authors report no conflicts of interest relevant to this article.

References

AMC Hanson KE, Arias CA, Englund JA, Lee MJ, Loeb M, Patel R, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19. : IDSA; 2020. Available at: https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnosis/. Accessed 07/15/2020.

AMP. SARS-CoV-2 molecular testing: summary of recent SARS-CoV-2 molecular testing survey. : Association for Molecular Pathology; 2020. Available at: https://www.amap.org/advisory/sars-cov-2-survey/. Accessed 07/15/2020.

Arar GF BM, Bizri NA, Ghizzawi L. Testing for COVID-19: when, who, and what test?. Lebanese Med J 2020;68:16–26.

Axell-House DB, Lavingia R, Rafferty M, Clark E, Amirian ES, Chiao EY. The estimation of time from symptom to SARS-CoV-2 molecular testing: summary of recent SARS-CoV-2 molecular testing survey. J Clin Virol 2020;129:104474.

Babiker A, Myers CW, Hill CE, Guarner J. SARS-CoV-2 testing. Am J Clin Pathol 2020;154:201–7.

Broughton JP, Deng X, Yu G, Fasching CL, Singh J, Streithorst J, et al. Rapid detection of 2019 novel coronavirus SARS-CoV-2 using a CRISPR-based DETECTR lateral flow assay 2020. doi: 10.1101/2020.03.06.20032334.30 2020.03.06.20032334.

Bulterys PL, Garamani N, Stevens B, Sahee MR, Huang CH, Hogan CA, et al. Comparison of SARS-CoV-2 diagnostic tests: the use of the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2. J Clin Virol 2020;129:104427.

Chen JH-K, Yip CC-Y, Chan JF-W, Poon BW-S, To KK-W, Chan K-H, et al. Clinical performance of the luminex xTAGS AR-CoV Expanded Panel for SARS-CoV-2 detection in nasopharyngeal specimens of COVID-19 patients in Hong Kong. J Clin Microbiol 2020;58:e00936–20. doi: 10.1128/JCM.00936-20.JCM.00936-20.

Craddock K, Lockhart M, Oeholt P, Fatica L, Landon L, Lieber M, et al. Clinical evaluation and utilization of multiple molecular in vitro diagnostic assays for the detection of SARS-CoV-2. Am J Clin Pathol 2020;154:201–7.

Cranney AR, Velu P, Satlin MJ, Fauntleroy KA, Callan K, Robertson A, et al. Comparison of two high-throughput reverse transcription-polymerase chain reaction systems for the detection of severe acute respiratory syndrome coronavirus 2. J Clin Microbiol 2020;58:e00890–20. doi: 10.1128/JCM.00890-20.

Creager HM, Cabrera B, Schaubelt A, Cox JL, Cushman-Vokoun AM, Shaker SM, et al. Clinical evaluation of the BioFire® Respiratory Panel 2.1 and detection of SARS-CoV-2. J Clin Virol 2020;129:104538.

Degli-Angeli E, Dragovan J, Huang ML, Lucid D, Cloherty G, Jerome KR, et al. Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance. J Clin Virol 2020;129:104474.

Ettevant S, Bal A, Escuret V, Bengel-Pesce K, Bouscambert M, Cheynet V, et al. Performance assessment of SARS-CoV-2 PCR assays developed by WHO referral laboratories. J Clin Med 2020;9:1817.

FDA. Emergency Use Authorization: Emergency Use Authorization (EUA) information, and list of all current EUAs. : U.S. Food & Drug Administration; 2020. Available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization Accessed 07/15/2020.

Garg A, Ghoshal U, Patel SS, Singh DV, Arya AK, Vasanth S, et al. Evaluation of seven commercial RT-PCR kits for COVID-19 testing in pooled clinical specimens. J Med Virol 2021;93:2281–6.

Harrington A, Cox B, Snowden J, Bakst J, Ley E, Grajales P, et al. Comparison of Abbott ID now and Abbott m2000 methods for the detection of SARS-CoV-2 from nasopharyngeal and Nasal Swabs from symptomatic patients. J Clin Microbiol 2020;58:e00798–20.e00798-20.

Liebeman JA, Pepper G, Nacache SN, Huang ML, Jerome KR, Greninger AL. Comparison of commercially available and laboratory-developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories. J Clin Microbiol 2020;58:e00821–20.e00821-20.

Liebeman JA, Pepper G, Nacache SN, Huang M-L, Jerome KR, Greninger AL. Comparison of commercially available and laboratory-developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories. J Clin Microbiol 2020;58:e00821–20.e00821-20.

Mitchell SL, George KS. Evaluation of the COVID19 ID NOW EUA assay. J Clin Virol 2020;128:104429–104429.

Mitchell SL, George KS, Rhodes DD, Butler-Wu SM, Dharmarha V, McNult P, et al. Understanding, verifying, and implementing emergency use authorization molecular diagnostics for the detection of SARS-CoV-2 RNA. J Clin Microbiol 2020;58:e00795–20.e00795-20.

Moore NM, Li H, Schejbal D, Lindsey J, Hayden M. Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCoV RT-PCR assay for the qualitative detection of SARS-CoV-2 from upper respiratory tract specimens. medRxiv 2020. doi: 10.1101/2020.05.02.20058740. 2020.05.02.20058740.

Moran A, Davis KG, Marushek C, Clagis C, Francoisi N, Teske V, et al. Clinical evaluation of SARS-CoV-2 using the cepheid Xpert xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 assays. J Clin Microbiol 2020. doi:10.1128/JCM.00772-20:JCM.00772-20.

Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC. Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays. J Clin Virol 2020;130:104578.

Onwuamah CK, Okwuarie AP, Salu OB, Shaiou JB, Nidoho N, Amoo SO, et al. Comparative performance of SARS-CoV-2 real-time PCR diagnostic assays on samples from Lagos, Nigeria. PLoS One 2021;16:1.e0246637.

Patel R, Babady E, Theel ES, Storch GA, Pinksy BA, St. George K, et al. Report from the American society for microbiology COVID-19 international summit, 23 March 2020. Value of diagnostic testing for SARS-CoV-2/CVID-19. mBio 2020;11.e00772-20.e00772-20.

Pham J, Meyer S, Nguyen C, Williams A, Hunsicker M, McHardy I, et al. Performance characteristics of a high-throughput automated transcription- mediated amplification test for SARS-CoV-2 detection. J Clin Microbiol 2020;58:e01669–20.e01669-20.

Poljak M, Korva M, Knop Gaipr N, Fujs Komlo S, Sagadin M, Ursic T, et al. Clinical evaluation of the Cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the Midst of the COVID-19 pandemic. J Clin Microbiol 2020;58:e00599–20.e00599-20.

Pujadas E, Ibeib N, Hernandez MM, Waluszko A, Siderenko T, Flores V, et al. Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche Cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test. J Med Virol 2020;92:10139E. doi: 10.1002/jmv.25853.

Rhoads DD, Cherian SS, Roman K, Stempak LM, Schnotz CL, Sadri N. Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA emergency use authorization methods for the detection of SARS-CoV-2 from nasopharyngeal and Nasal Swabs from individuals diagnosed with COVID-19. J Clin Microbiol 2020;58:e00760–20.e00760-20.

Rhoads DD, Cherian SS, Roman K, Stempak LM, Schnotz CL, Sadri N. Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of
SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19. J Clin Microbiol 2020. doi: 10.1128/JCM.00760-20.
Smith E, Zhen W, Manji R, Schron D, Duong S, Berry GJ. Analytical and clinical comparison of three nucleic acid amplification tests for SARS-CoV-2 detection. bioRxiv 2020. doi: 10.1101/2020.05.14.097311.
Taylor SC, Lapierriere G, Germain H. Droplet digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data. Sci Rep 2017;7:2409.
Uhteg K, Jarrett J, Richards M, Howard C, Morehead E, Geahr M, et al. Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays. J Clin Virol 2020;127:104384-104384.
WHO. Coronavirus disease (COVID-19) outbreak. World Health Organization; 2020. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Accessed 07/15/2020.
Yip CC-Y, Sridhar S, Cheng AK-W, Leung K-H, Chai GK-Y, Chen JH-K, et al. Evaluation of the commercially available LightMix Modular E-gene kit using clinical and proficiency testing specimens for SARS-CoV-2 detection. J Clin Virol 2020;129:104476.
Zhen W, Manji R, Smith E, Berry GJ. Comparison of four molecular in vitro diagnostic assays for the detection of SARS-CoV-2 in nasopharyngeal specimens. J Clin Microbiol 2020;58:e00743–20. doi: 10.1128/JCM.00743–20;JCM.00743–20.